Aciclovir extended release - Vectans Pharma

Drug Profile

Aciclovir extended release - Vectans Pharma

Alternative Names: Aciclovir - Onxeo; Aciclovir extended release - Onxeo; Aciclovir Lauriad®; Aciclovir muco-adhesive buccal tablet - Onxeo; Acyclovir extended release - Onxeo; Acyclovir Lauriad® 50mg (Sitavir) - Onxeo; BA 021; Labiriad; Sitavig; Sitavir®

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BioAlliance Pharma
  • Developer Cipher Pharmaceuticals; Vectans Pharma
  • Class Antivirals; Hypoxanthines; Small molecules
  • Mechanism of Action DNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Herpes labialis

Highest Development Phases

  • Marketed Herpes labialis

Most Recent Events

  • 31 Jul 2017 Vectans Pharma acquires Aciclovir extended release from Onxeo
  • 16 Feb 2016 Preregistration for Herpes labialis (Reccurent) in Canada (Buccal) before February 2016
  • 16 Feb 2016 Health Canada accepts NDA for acyclovir extended release for Herpes labialis (Recurrent) for review
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top